Cell Therapy News Volume 11.45 | Nov 22 2010

Rare Disease Reveals New Path for Creating Stem Cells 
Researchers have found that by mimicking a rare genetic disorder in a dish, they can rewind the internal clock of a mature cell and drive it back into an adult stem cell stage. [Press release from Harvard Medical School discussing online prepublication in Nature Medicine]

Educational Webinar on NSG Mice
The Jackson Laboratory
December 2, 2010

Interested in recruiting talented individuals? Post your career opportunities in Cell Therapy News at no cost. Contact us at info@connexoncreative.com

Follow us on Twitter! @CellTherapyNews

Embryonic Stem Cell Culturing Grows from Art to Science
A team of researchers reports the development of a fully defined culture system that promises a more uniform and, for cells destined for therapy, safer product. [Press release from the University of Wisconsin-Madison discussing online prepublication in Nature Methods]
 
Gene Therapy for Metastatic Melanoma in Mice Produces Complete Remission, Researchers Report
A potent anti-tumor gene introduced into mice with metastatic melanoma has resulted in permanent immune reconfiguration and produced a complete remission of their cancer. [Press release from Indiana University School of Medicine discussing online prepublication in the Journal of Clinical Investigation]
 
How Do Neural Stem Cells Decide What to Be — and When?
Researchers at Duke-NUS Graduate Medical School in Singapore have uncovered a novel feedback mechanism that controls the delicate balance of brain stem cells. Zif, a newly discovered protein, controls whether brain stem cells renew themselves as stem cells or differentiate into a dedicated type of neuron. [Press release from EurekAlert! discussing online prepublication in Developmental Cell]

Discovery in How HIV Thwarts the Body’s Natural Defense Opens Up New Target for Drug Therapies
Researchers at Rush University Medical Center have discovered the reason why natural killer cells are powerless against HIV. [Press release from EurekAlert! discussing online prepublication in Cell Host and Microbe]

Using Gene Therapy to Prevent Heart Failure
A Nova Southeastern University researcher has discovered how to use gene therapy to block a protein that can contribute to heart failure. [Press release from ScienceDaily discussing online prepublication in the Journal of the American College of Cardiology]

Origin of Cells Associated with Nerve Repair Discovered
Scientists have discovered the origin of a unique type of cell known for its ability to support regeneration in the central nervous system. [Press release from the University of Cambridge discussing online prepublication in the Proceedings of the National Academy of Sciences USA]

New Study into Bladder Regeneration Heralds Organ Replacement Treatment
Researchers have developed a medical model for regenerating bladders using stem cells harvested from a patient's own bone marrow. [Press release from EurekAlert! discussing online prepublication in Stem Cells]

Bioengineers Provide Adult Stem Cells with Friendly Environment: Simultaneous Chemical, Electrical and Mechanical Cues
Bioengineers have achieved the “Triple Crown” of stem cell culture — they created an artificial environment for stem cells that simultaneously provides the chemical, mechanical and electrical cues necessary for stem cell growth and differentiation. [Press release from the University of California, San Diego discussing online prepublication in Advanced Functional Materials]
 
Umbilical Cord Cells May Treat Arthritis, Studies Suggest
Umbilical cord stem cells may be useful in the treatment of rheumatoid arthritis. Animal and in vitro experiments have shown that mesenchymal stem cells taken from umbilical cord blood can suppress inflammation and attenuate collagen-induced arthritis. [Press release from EurekAlert! discussing online prepublication in Arthritis Research and Therapy]
 
Stem Cell Patch May Result in Improved Function Following Heart Attack
Researchers have found that applying a stem cell-infused patch together with overexpression of a specific cell instruction molecule promoted cell migration to damaged cardiac tissue following heart attack and resulted in improved function in animal models. [Press release from the University of Cincinnati discussing research presented at the American Heart Association’s Scientific Sessions 2010]
 
Celladon Corporation Announces MYDICAR® Enzyme Replacement Therapy for Advanced Heart Failure Provides Sustained Clinical Improvements in Patients for 12 Months Compared with Placebo
Celladon Corporation announced that 12-month data from its Phase II CUPID clinical trial of MYDICAR® demonstrated significant improvements in clinical outcomes and key disease markers in advanced heart failure patients treated with the genetically-targeted enzyme replacement therapy. [Press release from Celladon Corporation discussing research presented at the American Heart Association’s Scientific Sessions 2010]
 
Adipose-Derived Regenerative Cells Improve Cardiac Functional Capacity at 18 Months in Chronic Ischemic Heart Disease Patients
Adipose tissue-derived regenerative cells obtained using the Celution® System demonstrated a statistically significant improvement in cardiac functional capacity at 18 months in Cytori's PRECISE trial for chronic myocardial ischemia. [Press release from Cytori Therapeutics, Inc. discussing research presented at the American Heart Association’s Scientific Sessions 2010]
 
Researchers Report Cardiac Stem Cells as Safe, Effective in Heart Failure Treatment
Patients who have undergone heart bypass surgery are experiencing improved heart function through post-operative transfusions of their own stem cells. [Press release from the University of Louisville discussing research presented at the American Heart Association’s Scientific Sessions 2010]

Regenerative Stem Cell Therapy Offers New Hope for Treating Cardiovascular Disease
Researchers are revolutionizing treatment of cardiovascular disease by utilizing patients’ own stem cells to regenerate heart and vascular tissue. [Press release from Northwestern Memorial Hospital discussing research presented at the American Heart Association’s Scientific Sessions 2010]
 
Experimental Gene Therapy Did Not Prevent Amputation or Death in Patients with Peripheral Vascular Disease
Gene therapy did not prevent amputations or death among patients with severe obstruction in leg arteries and resulting foot ulcers. [American Heart Association Press Release]
 
Organs Made from Scratch
Growing living tissue and organs in the lab would be a life-saving trick. Researchers have taken a step toward this goal by coming up with a way to make “building blocks” containing different kinds of tissue that can be put together. [MIT Technology Review]
 
Aastrom Presents Positive Second Interim Analysis of Phase IIb RESTORE-CLI Clinical Trial
Aastrom Biosciences, Inc. announced that an interim analysis of all 86 patients enrolled in the company's Phase IIb RESTORE-CLI clinical trial shows that the study achieved both its primary safety endpoint and primary efficacy endpoint of time to first occurrence of treatment failure. [Press release from Aastrom Biosciences, Inc. discussing research presented at the 37th Annual Symposium on Vascular and Endovascular Issues]

CURRENT PUBLICATIONS (Ranked by Impact Factor of the Journal)

Conversion of Vascular Endothelial Cells into Multipotent Stem-Like Cells
Researchers show that vascular endothelial cells can transform into multipotent stem-like cells by an activin-like kinase-2 receptor-dependent mechanism. [Nat Med]

A Defined Glycosaminoglycan-Binding Substratum for Human Pluripotent Stem Cells
Results indicate that synthetic substrates that recognize cell-surface glycans can facilitate the long-term culture of pluripotent stem cells. [Nat Methods]

Transplantation of Mouse HSCs Genetically Modified to Express a CD4-Restricted TCR Results in Long-Term Immunity that Destroys Tumors and Initiates Spontaneous Autoimmunity
Results demonstrate the creation of what researchers believe to be a novel translational model of durable lentiviral gene transfer that results in long-term effective immunity. [J Clin Invest]
 
Interplay Between the Transcription Factor Zif and aPKC Regulates Neuroblast Polarity and Self-Renewal
Researchers have identified a zinc-finger protein, Zif, which is required for the expression and asymmetric localization of atypical protein kinase C (aPKC). aPKC displays ectopic cortical localization with upregulated protein levels in dividing zif mutant neuroblasts, leading to neuroblast overproliferation. [Dev Cell]
 
Degranulation of Natural Killer Cells Following Interaction with HIV-1-Infected Cells Is Hindered by Downmodulation of NTB-A by Vpu
Researchers show that triggering the natural killer (NK) cell coactivation receptor NK-T- and -B cell antigen (NTB-A) alongside NKG2D promotes NK cell degranulation. [Cell Host Microbe]
 
Neural Crest Origin of Olfactory Ensheathing Glia
Results raise the possibility that patient-derived neural crest stem cells could in the future provide an abundant and accessible source of autologous olfactory ensheathing cells for cell transplantation therapy for the injured central nervous system. [Proc Natl Acad Sci U S A]

Dynamic Electromechanical Hydrogel Matrices for Stem Cell Culture
Researchers report the development of hydrogel based multifunctional matrices that not only provide three-dimensional structural support to the embedded cells but also can simultaneously provide potentially beneficial dynamic mechanical and electrical cues to the cells. [Adv Funct Mater]

Therapeutic Potential of Human Umbilical Cord Mesenchymal Stem Cells in the Treatment of Rheumatoid Arthritis
Human umbilical cord (UC)-mesenchymal stem cells (MSCs) suppressed the various inflammatory effects of fibroblast-like synoviocytes and T cells of rheumatoid arthritis in vitro, and attenuated the development of collagen-induced arthritis in vivo, strongly suggesting that UC-MSCs might be a therapeutic strategy in rheumatoid arthritis. [Arth Res Ther]
 
Identification of Hematopoietic Stem Cell-Specific miRNAs Enables Gene Therapy of Globoid Cell Leukodystrophy
By incorporating miR-126 target sequences into a GALC-expressing vector, researchers suppressed GALC expression in hematopoietic stem cell (HSCs) while maintaining robust expression in mature hematopoietic cells. This approach protected HSCs from GALC toxicity and allowed successful treatment of a mouse globoid cell leukodystrophy (GLD) model, providing a rationale to explore HSC-based gene therapy for GLD. [Sci Transl Med]

European Research Body to Get New Head
The European Research Council is about to get a new leader, although not in the form most people expected. Helga Nowotny, chair of the ERC’s Scientific Council, a new secretary-general has been chosen to replace Andreu Mas-Colell, who stepped down for personal reasons in September. [European Research Council, European Union]

U.S. Genome Institute Takes a Clinical Approach
To date, the large-scale sequencing program of the National Human Genome Research Institute in Bethesda, Maryland, has mainly supported research at a handful of big U.S. sequencing centers. Although funding for those projects will continue, some money will now be diverted to smaller efforts that ask more-targeted questions about the health and clinical applications of sequencing. [National Human Genome Research Institute, United States]
 
AHRQ's Career Development and Postdoctoral Training Awards for Comparative Effectiveness Research [Pub. No. 10(11)-P010-EF] [Agency for Healthcare Research and Quality, United States]

CaridianBCT Collaborates with CASCADE Consortium
CaridianBCT announced its collaboration agreement with the Cultivated Adult Stem Cell Alternative for Damaged tissuE (CASCADE) consortium, a European Union project consisting of 16 organizations, to continue the development of culturing adult stem cells for clinical applications. [CaridianBCT Press Release]
 
Stratophase Collaborates with LGC on Real-Time Monitoring of 3D Cell Culture Growth
By using Stratophase’s innovative SpectroSens insertion probe, LGC has demonstrated its potential to improve the monitoring of cell growth in a 3D culture by enabling real-time measurement of nutrient metabolism and the build-up of waste products. [Stratophase Limited Press Release]
 
ICON and Proteome Sciences Partner for the Delivery of Comprehensive Biomarker Solution
ICON plc and Proteome Sciences announced the formation of a strategic alliance to provide pharmaceutical companies with an expanded biomarker solution to allow earlier assessments in the development of new medicines. [ICON plc Press Release]

Pfizer Launches Global Centers for Therapeutic Innovation, a Network of Research Partnerships, with University of California, San Francisco
Pfizer Inc. announced the establishment of the Global Centers for Therapeutic Innovation, an entrepreneurial network of partnerships with leading academic medical centers to transform research and development by accessing leading translational researchers. [Pfizer Inc. Press Release]
 
Mayo Clinic to License Vaccine Technology to Seattle Startup
TapImmune Inc. said it reached a deal to license Mayo Clinic technology that will help the company develop a vaccine that it says can prompt the body’s immune system to mount an aggressive attack on breast cancer and smallpox. [MedCity News]
 
Eisai and FORMA Therapeutics Enter into Broad Drug Discovery Collaboration
Eisai Inc. and FORMA Therapeutics announced that the two companies have signed a strategic drug discovery collaboration. [FORMA Therapeutics, Inc. Press Release]

Genzyme Announces Agreement to Sell Diagnostics Business to Sekisui Chemical Company
Genzyme Corporation announced that it has entered into an asset purchase agreement under which Sekisui Chemical Co., Ltd. will acquire Genzyme’s Diagnostic products business for $265 million in cash. [Genzyme Corporation Press Release]
 
LabCorp's Acquisition of Genzyme Genetics Clears Antitrust Review
Laboratory Corporation of America® Holdings announced that it has received early termination from the Federal Trade Commission of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 applicable to the acquisition of Genzyme Genetics, a business unit of Genzyme Corporation by LabCorp. [Laboratory Corporation of America Holdings Press Release]
 
ARC Future Fellows Shine Light on Cell Life and Death
Researchers from the Walter and Eliza Hall Institute have received $4.45 million in Australian Research Council (ARC) funding to further fundamental discoveries about cell life and death, and the changes that occur in cells that give rise to cancer. [The Walter and Eliza Hall Institute of Medical Research Press Release]

Cerulean Pharma Inc. Closes $24 Million in Series C Financing
Cerulean Pharma Inc. announced that the Company has closed a $24 million Series C financing led by Lilly Ventures, with participation from all other existing investors including Polaris Venture Partners, Venrock, Lux Capital, and Bessemer Venture Partners. [Cerulean Pharma Inc. Press Release]

Stratatech Awarded $3.5 Million to Continue Development of Infection-Fighting Skin Substitute
Stratatech Corporation, a privately-held regenerative medicine company, announced that it has been awarded a $3.5 million Fast-Track Small Business Innovation Research grant to expand the development of its anti-infective living human skin substitute. [Business Wire]
 
Advanced Cell Technology Receives FDA Clearance for the First Clinical Trial Using Embryonic Stem Cells to Treat Macular Degeneration
Advanced Cell Technology, Inc. announced that the U.S. Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug application to immediately initiate a Phase I/II multicenter clinical trial using retinal cells derived from human embryonic stem cells to treat patients with Stargardt’s Macular Dystrophy. [Advanced Cell Technology, Inc. Press Release]
 
Bayer and Regeneron Report Positive Top-Line Results of Two Phase III Studies with VEGF Trap-Eye in Wet Age-Related Macular Degeneration
Regeneron Pharmaceuticals, Inc. and Bayer HealthCare announced that in two parallel Phase III studies in patients with the neovascular form of age-related macular degeneration, all regimens of VEGF Trap-Eye (aflibercept ophthalmic solution), including VEGF Trap-Eye dosed every two months, successfully met the primary endpoint compared to the current standard of care, ranibizumab dosed every month. [Regeneron Pharmaceuticals, Inc. Press Release]
 
ReNeuron Announces First Patient Treated in Landmark Stroke Stem Cell Clinical Trial
ReNeuron Group plc announced that the first patient has been treated with the Company’s ReN001 stem cell therapy for stroke in a ground-breaking UK clinical trial. [ReNeuron Group Press Release]

Human Genome Sciences and GlaxoSmithKline Announce Vote of FDA Advisory Committee to Recommend Approval of Benlysta® for Systemic Lupus Erythematosus
Human Genome Sciences, Inc. and GlaxoSmithKline PLC announced that the Arthritis Advisory Committee of the U.S. Food and Drug Administration (FDA) has voted 13 to 2 to recommend that the FDA approve BENLYSTA® (belimumab) for the treatment of autoantibody-positive patients with active systemic lupus erythematosus. [Human Genome Sciences, Inc. Press Release]
 
Immunovaccine Inc. Announces Phase I/II Clinical Plan for DPX-Survivac to Target Ovarian Cancer
Immunovaccine Inc. announced that it will focus the Phase I/II clinical development plan for DPX-Survivac on ovarian cancer. [Immunovaccine Inc. Press Release]
 
Roche Announces Implementation Plans for Its Operational Excellence Program
Following a comprehensive portfolio review, Roche will discontinue certain activities in research and early development. These include RNA interference research in Kulmbach, Germany, and in Nutley, New Jersey, and Madison, Wisconsin, in the U.S. [Roche Press Release]

Office of Biotechnology Activities Recombinant DNA Research: Proposed Actions Under the NIH Guidelines for Research Involving Recombinant DNA Molecules (NIH Guidelines) (FR Doc. 2010-28698)

Functional Genetics, Epigenetics, and Non-Coding RNAs in Drug Addiction (R03) (PA-11-035)

Office of the National Coordinator for Health Information Technology; HIT; Standards Committee's Workgroup Meetings; Notice of Meetings (FR Doc. 2010-29221)
 
Submission for OMB Review; Comment Request; NIH NCI Central Institutional Review Board (CIRB) Initiative (NCI) (FR Doc. 2010-28883) 

Institutional Clinical and Translational Science Award (U54) (RFA-RM-10-020) 

National Heart, Lung, and Blood Institute; Notice of Closed Meeting (FR Doc. 2010-28984)
 
National Center for Research Resources; Notice of Closed Meeting (FR Doc. 2010-29197)
 
Office of the Director, National Institutes of Health; Notice of Meeting (FR Doc. 2010-28704)
 
Center for Scientific Review; Notice of Closed Meetings (FR Doc. 2010-28985) 

Center for Scientific Review; Notice of Closed Meetings (FR Doc. 2010-29198)
 
National Committee on Vital and Health Statistics: Meeting (FR Doc. 2010-29216)
 
National Cancer Institute; Notice of Closed Meeting (FR Doc. 2010-29363)

Complete List of Currently Approved NDA and ANDA Application Submissions

Complete List of Currently Approved Premarket Approvals 

Complete List of Licensed Products and Establishments  

Public Workshop on Cell and Gene Therapy Clinical Trials in Pediatric Populations — Presentations Added

FOOD AND DRUG ADMINISTRATION (United States)

FDA Seen Tougher on Drug Risks Post-Avandia
Regulators appear to be increasing their scrutiny of product risks after cases like the bitter debate over the diabetes pill Avandia, industry executives and experts said.
 
FDA Approves New Treatment Option for Late-Stage Breast Cancer
The U.S. Food and Drug Administration today approved Halaven (eribulin mesylate) to treat patients with metastatic breast cancer who have received at least two prior chemotherapy regimens for late-stage disease.
 
Cardiovascular and Renal Drugs Advisory Committee; Notice of Meeting

EUROPEAN MEDICINES AGENCY (European Union)

Committee for Advanced Therapies Adopts Five-Year Work Program to Foster Development of Advanced Therapies
The European Medicines Agency’s Committee for Advanced Therapies has unveiled a Work Program to 2015, intended to help increase the number of advanced-therapy medicinal products that make it from the early research stage to the market.

European Medicines Agency Confirms That Presence of Unexpected Viral DNA in Live Attenuated Vaccines Does Not Raise Public Health Concerns
The European Medicines Agency’s Committee for Medicinal Products for Human Use has finalized a review on the impact of the detection, using a new testing method, of DNA fragments from viral agents in some live attenuated vaccines.

Meeting Highlights from the Committee for Medicinal Products for Human Use (CHMP), 15-18 November 2010

THERAPEUTIC GOODS ADMINISTRATION (Australia)

Review to Improve Transparency of the TGA

American Association for Cancer Research (AACR) Tumor Immunology – Basic and Clinical Advances
November 30-December 3, 2010
Miami, United States

NEW Vaccines Europe 2010
December 1-2, 2010
London, United Kingdom

2nd European Association for Cardio-Thoracic Surgery (EACTS) Meeting on Cardiac and Pulmonary Regeneration
December 3-4, 2010
Vienna, Austria

3rd Annual BioPartnering China
December 5-7, 2010
Shanghai, China

Tissue Engineering & Regenerative Medicine International Society (TERMIS) – North America (TERMIS-NA) 2010 Annual Conference
December 5-8, 2010
Orlando, United States

5th Annual Stem Cell Meeting on the Mesa
December 7, 2010
La Jolla, United States

Genesis 2010
December 9, 2010
London, United Kingdom

NEW Safety Symposium organized by the NIH RAC and Co-hosted by CliniGene: Retroviral and Lentiviral Vectors for Long-Term Gene Correction: Clinical Challenges in Vector and Trial Design
December 9-10, 2010
Bethesda, United States

NEW 4th International Conference on the Mechanics of Biomaterials and Tissues
December 11-14, 2010
Waikoloa, Hawaii

The American Society for Cell Biology 50th Annual Meeting
December 11-15, 2010
Philadelphia, United States

Partnering for Cures
December 14-15, 2010
New York, United States

Pharmacology in Stem Cells Research and Regenerative Medicine
December 17, 2010
London, United Kingdom

The 3rd Guangzhou International Conference on Stem Cell Biology and Regenerative Medicine
December 17-19, 2010
Guangzhou, China

Functional Consequences of Structural Variation in the Genome
January 8-13, 2011
Steamboat Springs, United States

NEW 4th Annual OneMedForum
January 11-13, 2011
San Francisco, United States

COGEM Symposium: GM Viruses as Medicine: Panacea or Pandora's Box?
January 20, 2011
Amsterdam, The Netherlands

Extracellular Matrix and Cardiovascular Remodeling
January 23-28, 2011
Tahoe City, United States

5th Annual Stem Cells and Regenerative Medicine World Congress
January 24-25, 2011
San Diego, United States

BIO Asia International Partnering Conference
January 24-25, 2011
Tokyo, Japan

Phacilitate 7th Annual Cell & Gene Therapy Forum 2011
January 24-26, 2011
Washington, D.C., United States

Phacilitate 9th Annual North American Vaccine Forum
January 24-26, 2011
Washington, D.C., United States

IQPC’s 4th Biobanking Conference
January 24-26, 2011
Philadelphia, United States

Keystone Symposia: Stem Cells in Development, Tissue Homeostasis and Disease
January 30-February 4, 2011
Santa Fe, United States

16th Proteomics Symposium
February 3-6, 2011
Lorne, Australia

36th Lorne Conference on Protein Structure and Function
February 6-10, 2011
Lorne, Australia

CMC Workshop: Translating Science into Successful Regulatory Submissions
February 7-9, 2011
Washington, D.C., United States

Stem Cell Research Forum of India 2nd Annual Meeting
February 8-11, 2011
Bangalore, India

23rd Lorne Cancer Conference
February 10-12, 2011
Lorne, Australia

32nd Lorne Genome Conference
February 13-15, 2011
Lorne, Australia

BMT Tandem Meetings (ASBMT/CIBMTR)
February 17-21, 2011
Honolulu, Hawaii

1st Annual Clinical Meeting of the Cell Society
February 18-19, 2011
La Jolla, United States

NEW SMi Stem Cells 2011 – Innovation & Commercialisation
February 23-24, 2011
London, United Kingdom

Molecular Medicine Tri-Conference: Stem Cells – Revolutionizing Regenerative Medicine and Personalized Therapy 2011
February 23-25, 2011
San Francisco, United States

Molecular Medicine Tri-Conference: Inaugural Circulating Tumor Cells for Cancer Detection, Diagnosis, Prognosis and Treatment
February 23-25, 2011
San Francisco, United States

American Association for Cancer Research (AACR) Targeting PI3K/mTOR Signaling in Cancer
February 24-27, 2011
San Francisco, United States

NEW Annual Meeting of the International Society for Cell & Gene Therapy of Cancer (ISCGT)
February 27-March 1, 2011
Doha, Qatar

9th Annual BioPartnering North America
February 27-March 1, 2011
Vancouver, Canada

18th Conference on Retroviruses and Opportunistic Infections (CROI 2011)
February 27-March 2, 2011
Boston, United States

6th Annual Stem Cell Summit
March 1, 2011
New York, United States

American Association for Cancer Research (AACR) Stem Cells, Development, and Cancer
March 3-6, 2011
Vancouver, Canada

Keystone Symposia: Stem Cells, Cancer and Metastasis
March 6-11, 2011
Dillon, United States

NEW Cell Therapy Summit Europe (CTS Europe)
March 10-11, 2011
Maastricht, The Netherlands

BIO-Europe Spring 2011
March 14-16, 2011
Milan, Italy

The 6th International Conference on Oncolytic Viruses as Cancer Therapeutics
March 16-19, 2011
Las Vegas, United States

15th Annual Hilton Head Workshop – Regenerative Medicine, Innovations for Clinical Applications
March 16-19, 2011
Hilton Head Island, United States

HIV Evolution, Genomics and Pathogenesis
March 20-25, 2011
Whistler, Canada

StemCONN 11
March 22, 2011
Farmington, United States

United Kingdom National Stem Cell Network 2011 Annual Scientific Conference
March 30-April 1, 2011
York, United Kingdom

10th Annual New England Science Symposium
April 1, 2011
Boston, United States

American Association for Cancer Research (AACR) 102nd Annual Meeting 2011
April 2-6, 2011
Orlando, United States

NEW Clinical Gene Transfer: State of the Art Conference and e-Chips European Congress on Human iPS Cells
April 7-9, 2011
Paris, France

5th RNAi & miRNA World Congress
April 26-27, 2011
Boston, United States

3rd Epigenetics World Congress
April 26-27, 2011
Boston, United States

Inaugural Next-Gen Sequencing Congress
April 26-27, 2011
Boston, United States

GTCbio 2nd International Conference on Cancer Immunotherapy & Immunomonitoring
May 2-5, 2011
Budapest, Hungary

Australasian Gene Therapy Society (AGTS) 7th Meeting
May 4-6, 2011
Melbourne, Australia

BioPartnering India
May 4-6, 2011
Bangalore, India

2nd European Biomarkers Summit
May 18-19, 2011
London, United Kingdom

Inaugural Theranostics for Personalised Medicine
May 18-19, 2011
London, United Kingdom

International Society for Cellular Therapy (ISCT) 17th Annual Meeting
May 18-21, 2011
Rotterdam, The Netherlands

American Society of Gene and Cell Therapy (ASGCT) 14th Annual Meeting
May 18-22, 2011
Seattle, United States

13th Annual C21 BioVentures
May 24-26, 2011
Napa, United States

Gordon Research Conference: Viruses & Cells
May 29-June 3, 2011
Lucca (Barga), Italy

Visit our events page to stay up to date with the latest events in the cell, gene and immunotherapy community.

JOB OPPORTUNITIES

Lab Technologist – Human Embryonic and Induced Pluripotent Stem Cells (STEMCELL Technologies)

Lab Technologist – Tissue Culture (STEMCELL Technologies)

Product Manager – Pluripotent Stem Cells (STEMCELL Technologies)

Recruit Top Talent
Reach more than 11,000 potential candidates by posting your organization's career opportunities with Cell Therapy News at no cost.
Visit here to post your career opportunities.